Bauer takes role of president at Chemwerth

Formerly with Sandoz

Jeffrey Bauer has taken over as president of ChemWerth, a US supplier of active pharmaceutical ingredients for generic medicines.

Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.

Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.

ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like

Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Ingredients

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples
Analysis

Efficient extraction of proteins from bacterial cells

SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells
Ingredients

Roquette's Low Nitrite METHOCEL HPMC wins NIE New Ingredient award

The modified cellulose excipient is designed to significantly reduce nitrosamine formation risk in pharmaceutical formulations and took home first place in the Excipients/Non-Actives category at the NIE New Ingredient Awards
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Subscribe now